

Financial Disclosure

For: Shaun Goodman

Updated: January 3, 2018

Monetary amounts are on an annual basis

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company partially supports my University salary	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Canadian VIGOUR Centre (including support from AstraZeneca, Sanofi/Regeneron, Tenax, CSL)	2010-present	EXSCEL (2010-17), ODYSSEY Outcomes (2012-present), LEVO-CTS (2015-17), and AEGIS-2 (2016-present) trials	X								Including quarterly stipend directed to the St. Michael's Hospital Physician's Association
Duke Clinical Research Institute (including support from AstraZeneca, Sanofi/Regeneron, Tenax, CSL)	2010-present	EXSCEL, ODYSSEY Outcomes, LEVO-CTS, and AEGIS-2 trials					X				
Canadian Heart Research Centre and MD Primer	1996-present	Multiple clinical trials, observational registries, and continuing professional development programs	X					X			Including quarterly stipend directed to the St. Michael's Hospital Physician's Association
New York University	2012-present	ISCHEMIA trial		X							

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company partially supports my University salary	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Heart & Stroke Foundation of Ontario/University of Toronto	2011-present	Polo Chair, Division of Cardiology, Department of Medicine	X								Monthly stipend directed to the St. Michael's Hospital Physician's Association
Mayo Clinic	2012-present	TAILOR-PCI trial		X							
HCor	2015-present	TREAT trial		X							Steering Committee Member
Eli Lilly	2012-2016	ACCELERATE trial						X			National Coordinator stipend
AstraZeneca	2011-2016	ATLANTIC trial					X				National Coordinator stipend
Novartis	2011-2017	CANTOS trial		X							Funds cover study coordinator's salary
AstraZeneca	2010-2014	Canadian ACS Reflective		X							
AstraZeneca	2015-present	Canadian ACS Reflective II		X							
Bayer	2017-present	CONNECT AF+PCI		X							
Bayer	2012-2014	CONNECT AF		X							
Boehringer Ingelheim	2009-2013	FREEDOM AF		X							

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company partially supports my University salary	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Eli Lilly	2011-2015	COAPT		X							
Eli Lilly	2016-2017	ASCVD PCSK9 inhibitor trial					X				Executive Steering Committee member
Servier	2009-2017	CLARIFY					X				
Pfizer	2012-2017	REMINDER trial		X							Funds cover study coordinator's salary
Sanofi	2012-present	ODYSSEY Outcomes trial						X			Executive Steering Committee stipend
AstraZeneca	2013-present	TIGRIS study					X				Executive Steering Committee stipend
Revalerio	2013-2014	CHARGE-AMI					X				Executive Steering Committee stipend
Luitpold Pharmaceuticals	2017-present	HEART-FID					X				Data Monitoring Committee member
University Court of the University of Edinburgh	2014-present	ACS Risk Working Group Canadian study		X							
Matrizyme Pharma	2014-2016	TOSCA-5 trial					X				Data Monitoring Committee member

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company partially supports my University salary	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Ferring Pharmaceuticals	2015-present	Degarelix CV Outcome study					X				Executive Steering Committee member
Bristol-Myers Squibb/Pfizer	2015-present	AUGUSTUS trial					X				Executive Steering Committee member
Bristol-Myers Squibb/Pfizer	2016-present	OPTIMAL AF		X							
Amgen Pharmaceuticals	2015-present	GOAL and GOAL-2 registries		X							
GlaxoSmithKline	2014-2017	HARMONY trial					X				Data Monitoring Committee member
Tenax Pharmaceuticals	2015-2017	LEVO-CTS trial		X			X				Consultant for Tenax re Health Canada
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, EOCI, Fenix Group International, Ferring, Lilly, Merck, Sanofi, Servier	2013-present	Consulting/Advisory Boards/Rounds/Slide set development						X			

In accordance with the American Heart Association conflict of interest policies.

Column Explanations:

- (1) Funding is provided for my effort in research grants/ contracts for multi-center projects in which I serve in an executive function, this often is combined with Canadian operational responsibility. Remuneration for such work is received through the St. Michael's Hospital Physicians' Association/Department of Medicine at St. Michael's Hospital and the University of Toronto in Toronto, and Capital Health in Edmonton.
- (2) A research grant from this company or academic research organization supports the expenses associated with projects in the Canadian Heart Research Centre/MD Primer, and the Canadian VIGOUR Centre/University of Alberta where I am a consultant and Co-Director, respectively.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. The two columns represent annual payments of more or less than \$10,000 per year from this company.
- (4) I receive personal income for consulting and speaking engagements/rounds from this company. The two columns represent annual payments of more or less than \$10,000 from this company.
- (5) I personally receive no royalties from any industrial firm.
- (6) Neither me nor any member of my family have equity in any industrial firm.